No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
www.takeda.comNo one on the platform currently holds 4502.T.
No tracked institution reports a position in 4502.T as of their last filing.
No one on the platform has traded 4502.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.3% | 5.6% | — | — | — | |
| Rev. Growth % | -1.7% | 7.1% | ||||
| Profit Margin % | 4.3% | 4.9% | 6.1% | |||
| Free Cash Flow Margin % | 16.9% | 17.6% | 16.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $4.69T | +3.4% | $124.37 | $100.73–$152.23 | — | 13 |
| 2028 | $4.78T | +1.9% | $198.87 | $109.17–$297.21 | — | 13 |
| 2029 | $4.92T | +3.0% | $243.21 | $152.36–$347.76 | — | 12 |
| 2030 | $5.22T | +6.0% | $281.96 | $270.14–$298.46 | — | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $53.12 | $71.65 | +34.9% |
| 2026-05-13 | $-24.04 | $-15.58 | +35.2% |
| 2026-01-29 | $43.14 | $64.93 | +50.5% |
| 2025-10-29 | $21.61 | $-8.16 | -137.8% |
| 2025-07-29 | $50.79 | $81.38 | +60.2% |
| 2025-05-07 | $-8.59 | $-64.14 | -646.6% |
| 2025-01-30 | $25.86 | $14.92 | -42.3% |
| 2024-10-31 | $32.80 |
| $58.14 |
| +77.3% |
| +1.68% |
| $10.5B |
| — |
| 4523.TEisai Co., Ltd. | $4767.00 | +0.51% | $1.35T | — |
| 4543.TTerumo Corporation | $2242.50 | -0.88% | $3.31T | — |
Source: Financial Modeling Prep · peers by sector/industry